A Multicentre, Prospective, Open-label, Randomized Controlled Trial on the Efficacy and Safety of TheraSphereTM (Yttrium-90 Glass Microspheres) Compared to Conventional Transarterial Chemoembolization (cTACE) in Chinese Patients With Inoperable Hepatocellular Carcinoma

  • STATUS
    Recruiting
  • End date
    Aug 30, 2025
  • participants needed
    90
  • sponsor
    Boston Scientific Corporation
Updated on 21 October 2022

Summary

To evaluate the efficacy and safety of TheraSphereTM yttrium [90Y] glass microsphere in the Chinese patients with inoperable hepatocellular carcinoma.

Details
Condition Inoperable Hepatocellular Carcinoma
Treatment TheraSphere™ Yttrium-90 Glass Microspheres, conventional Transarterial Chemoembolization(cTACE)
Clinical Study IdentifierNCT05016245
SponsorBoston Scientific Corporation
Last Modified on21 October 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

≥18 and ≤80 age and provided study consent
Patients diagnosed with HCC and clinically evaluated as inoperable (as per local practice) or who refuse operation (ablation, hepatectomy and liver transplantation)
At least one well defined HCC tumor measurable by mRECIST in contrast-enhanced MRI
China liver cancer staging (CNLC) stage Ib~IIb
Child-Pugh ≤ B7
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
Tumor burden ≤50% of the total liver volume

Exclusion Criteria

Presence of extra-hepatic metastases or additional malignancies aside from HCC
Patients with hepatic artery malformation and unable to intubate hepatic artery
Patients who are allergic to contrast agents or have renal insufficiency (Serum creatinine>2mg/ml or Creatinine clearance<30mL/min) and are not suitable for injection of contrast agents
Severe pulmonary insufficiency (FEV1/FVC<50% or FEV1/predicting value<50% or MVV<50L/min)
AST and ALT >5 times upper limit of normal
Clinical manifestations of decompensated cirrhosis (Grade2/3 of ascites, gastrointestinal bleeding, hepatic encephalopathy, etc. according to EASL Clinical Practice Guidelines)
HCC invading biliary tract or causing biliary obstruction
uncorrectable coagulation dysfunction and severe hemogram abnormality [Prothrombin time (PT)>6 seconds above control or PT-International normalized ratio (INR)>2.5, WBC<3.0x109/L, PLT<50x109/L]
Infiltrative HCC tumor type
Bilobar HCC disease
Any presence of portal vein or hepatic veins or artery invasion
Occlusion of portal vein completely with less collateral vessels
Transjugular intrahepatic portosystemic shunt (TIPS) or Hepatic arterioportal fistula
Patients during pregnancy or lactation
Prior interventional therapy via hepatic artery or radiotherapy treatment for HCC
Tc-99m macroaggregated albumin (MAA) hepatic arterial perfusion scintigraphy shows any deposition to the gastrointestinal tract that may not be corrected by angiographic techniques
Radiation pneumonitis has been seen in patients receiving doses to the lungs greater than 30 Gy in a single treatment or greater than 50Gy in multiple treatment
The absorbed dose of lung may exceed 30Gy in preoperative evaluation
Receive any investigational therapy or anti-tumor therapy within 30 days prior to study enrollment
Any other reason in which the investigator believes that the patient is unsuitable to participate in this trial
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note